⚕️ Medical Disclaimer
**⚕️ Medical Disclaimer:** This article is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any medication.
What Is CagriSema?
CagriSema is Novo Nordisk's fixed-ratio combination of **semaglutide** (a GLP-1 receptor agonist) and **cagrilintide** (a long-acting amylin analog) in a single weekly subcutaneous injection. The REDEFINE 1 pivotal trial demonstrated **22.7% mean weight loss at 68 weeks** — the largest weight reduction ever reported for a single medication in an obesity trial (Lau et al., 2024, NEJM). FDA filing (NDA) was submitted in late 2024 with potential approval expected in 2025-2026.
*Last updated: March 2026*
How Does CagriSema Work? Dual Mechanism Explained
**Semaglutide component:** GLP-1 receptor agonist that suppresses appetite centrally (hypothalamic POMC/CART activation, NPY/AgRP inhibition), slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the same molecule in Ozempic and Wegovy.
**Cagrilintide component:** Long-acting acylated analog of amylin — a peptide co-secreted with insulin from pancreatic β-cells. Amylin suppresses glucagon secretion, slows gastric emptying through a different pathway than GLP-1, and activates the area postrema for satiety signaling. By combining two distinct satiety pathways, CagriSema achieves synergistic appetite suppression.
For semaglutide dosing on its own, see our [semaglutide dose calculator](/en/blog/semaglutide-dose-calculator) and [GLP-1 escalation guide](/en/blog/glp1-dose-escalation-guide).
CagriSema Clinical Results: REDEFINE Trials
| Trial | Population | Duration | Weight Loss | Comparison |
|---|---|---|---|---|
| REDEFINE 1 | Adults with obesity (BMI ≥30) | 68 weeks | -22.7% | Placebo: -2.3% |
| REDEFINE 2 | T2D + obesity | 68 weeks | -15.7% | Semaglutide alone: -12.2% |
| REDEFINE 3 | Sequential after semaglutide | 68 weeks | Additional -8% beyond sema | — |
Key finding from REDEFINE 2: CagriSema produced 3.5% MORE weight loss than semaglutide alone — demonstrating that the cagrilintide component adds meaningful incremental benefit through the amylin pathway.
CagriSema vs Tirzepatide vs Retatrutide: Next-Gen Comparison
| Feature | CagriSema | Tirzepatide (Mounjaro) | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 + Amylin | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Max Weight Loss | ~23% (68 wk) | ~22.5% (72 wk) | ~24% (48 wk, Phase 2) |
| Route | SubQ weekly | SubQ weekly | SubQ weekly |
| FDA Status | NDA filed (2024) | Approved (2023) | Phase 3 |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Muscle Preservation | Under study | Better than sema | Under study |
This is the new generation of obesity medicine. For current GLP-1 scheduling, see the [GLP-1 Scheduler Calculator](/en/glp1-scheduler).
Frequently Asked Questions
**When will CagriSema be available?** FDA NDA filed late 2024. Potential approval mid-2025 to early 2026. Brand name and pricing not yet finalized.
**Can I create my own CagriSema by combining semaglutide + cagrilintide?** This is not recommended. The fixed-ratio combination in CagriSema was specifically designed for optimal pharmacokinetics. Mixing separate vials introduces dosing inconsistencies.
**Is CagriSema better than tirzepatide?** Head-to-head trials have not been completed. Both achieve ~22-23% weight loss through different dual-mechanism approaches (GLP-1+amylin vs GLP-1+GIP).
**What are the side effects?** Similar to semaglutide: nausea, vomiting, diarrhea, constipation. The amylin component may add injection site reactions. Cardiovascular outcomes trials are ongoing.
**Will CagriSema be covered by insurance?** Pricing and coverage will be determined upon FDA approval. Expected to be in the same cost range as current branded GLP-1 agonists (~$1,000-1,500/month without insurance).